Cristina João

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 456 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Refractory Mantle-cell Lymphoma +7

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Simon Rule, Wojciech Jurczak, Mats Jerkeman et al. · Leukemia · 2018 · 95 citations · Full text

Lymphoid Neoplasia, Mantle Cell Lymphoma, Medicine +9

B Cell-Dependent TCR Diversification

Cristina João, Brenda M. Ogle, Carlota Gay-Rabinstein et al. · The Journal of Immunology · 2004 · 86 citations · Full text

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Cristina João, L.F. Porrata, David J. Inwards et al. · Bone Marrow Transplantation · 2006 · 70 citations

Regenerative Medicine, Mantle-cell Lymphoma, Lymphoid Neoplasia +14